Ceftobiprole demonstrates nearly full effectiveness against MRSA in the first US surveillance results since its FDA approval, though its performance against E. coli and Klebsiella pneumoniae depends heavily on resistance patterns. The data, presented at IDWeek 2026 (October 21–24, 2026 in Washington, DC), confirm the antibiotic’s strong position for treating methicillin-resistant Staphylococcus aureus infections while revealing significant weaknesses in broader Gram-negative coverage. The findings were published in a poster by the SENTRY Antimicrobial Surveillance Program, accessible via BusinessWire (accessed November 2, 2026).
The SENTRY Antimicrobial Surveillance Program analyzed isolates collected from US medical centers in 2025 and found 99% of MRSA samples remained susceptible to ceftobiprole. The drug received FDA clearance in April 2024 for three approved uses: S. aureus bacteremia (including right-sided infective endocarditis) in adults, acute bacterial skin infections in adults, and community-acquired bacterial pneumonia in adults and pediatric patients 3 months to younger than 18 years.
The ERADICATE trial, published in The New England Journal of Medicine (2023;389(15):1390–1401, doi:10.1056/NEJMoa2300220), had shown a 69.8% success rate at day 70—comparable to daptomycin with or without aztreonam, where the control arm achieved 68.7% success. The phase 3 study, which included both methicillin-resistant and methicillin-susceptible strains, established ceftobiprole’s noninferiority to standard therapies for Staphylococcus aureus bacteremia.
Innoviva Specialty Therapeutics secured US marketing rights in December 2024 and introduced the drug commercially in May 2025. The 2025 surveillance results now provide the first real-world evidence of susceptibility trends after launch. David Altarac, MD, Innoviva’s chief medical officer, described the findings as promising and aligned with preapproval research, emphasizing that the 99% MRSA susceptibility rate mirrored the drug’s performance in the ERADICATE trial.
Related Post: Study finds 15-20% endometrial cancer recurrence risk after treatment
Limited Gram-negative coverage raises treatment concerns
However, ceftobiprole’s effectiveness against Gram-negative bacteria shows clear limitations. It inhibited 73% of E. coli and K. pneumoniae isolates overall, but nearly all activity disappeared in strains producing extended-spectrum β-lactamases (ESBLs). This limitation forces clinicians to consider empiric treatment strategies carefully, particularly in pneumonia or mixed infections, where ESBL risk factors, such as prior antibiotic use, hospital stays, or invasive devices, may be present. Altarac recommended tailoring therapy based on local microbiology data, reinforcing standard antibiotic stewardship practices. He clarified that ceftobiprole is not an ESBL-directed agent, meaning its Gram-negative coverage is restricted to non-ESBL-producing strains, which accounted for the majority of susceptible isolates in the SENTRY data.
The drug now provides an alternative to ceftaroline for S. aureus bacteremia. While the ERADICATE trial confirmed ceftobiprole’s efficacy against both methicillin-resistant and methicillin-susceptible strains, no direct comparisons with ceftaroline have been published. Clinicians can now select between the two based on susceptibility testing, regional resistance patterns, and individual patient needs. Altarac highlighted that ceftobiprole’s approval expands the options for anti-MRSA β-lactam therapy, though its broader utility depends on local epidemiology and pathogen prevalence.
Real-world use highlights MRSA strength, ESBL weaknesses
With its commercial launch in May 2025, ceftobiprole transitions from clinical trials to broader clinical use. The 99% MRSA susceptibility rate remains a strong advantage, but the drug’s reduced activity against ESBL-producing strains presents a challenge. Facilities with high ESBL prevalence may still require combination therapies or alternative agents for complex infections. The SENTRY data show the need for ongoing surveillance to track emerging resistance trends, particularly as ceftobiprole’s adoption grows in high-risk settings.
Altarac emphasized that ongoing surveillance data will help refine treatment recommendations over time. The drug’s long-term role in clinical practice will depend on continued monitoring of resistance patterns and its integration into antibiotic stewardship programs.